Ask the experts
Although nerve damage and visual loss from glaucoma cannot usually be reversed, glaucoma is a disease that can generally be controlled. That is, treatment can make the intraocular pressure normal and, therefore, prevent or retard further nerve damage and visual loss. Treatment may involve the use of eyedrop medications, pills (rarely), laser, or incisional surgery.
In the United States, eyedrop medications are usually used first in treating most types of open-angle glaucoma. In contrast, in Europe, laser or surgery is sometimes the first choice of treatment. One or more types of eyedrops may have to be taken up to several times a day to lower intraocular pressure. These drops work either by reducing the production of the aqueous fluid (shutting the faucet) or by increasing the drainage of the fluid out of the eye. Each type of therapy has its benefits and potential complications.
It is important to remember that many patients at risk for glaucoma or who have glaucoma also may have other eye diseases such as cataract or macular degeneration. An ophthalmologist can determine whether any visual loss that one is experiencing is being caused by glaucoma or by other eye abnormalities.
There are many patients whose examination reveals elevated eye pressure and increased risk for glaucoma but no definite evidence of eye damage from glaucoma. These patients have what is termed ocular hypertension (OHT), formerly known as "pre-glaucoma" or "glaucoma suspect." Patients with OHT have no visual field loss but are at increased risk of glaucoma because of the presence of elevated intraocular pressure or optic nerve changes visible on ophthalmoscopy or imaging. Some of the patients with OHT require treatment. These patients with OHT need to be observed frequently so that treatment can be initiated prior to the onset of glaucomatous damage.
Read our full medical article to learn more about glaucoma types, symptoms, signs, causes, and treatments.
"Open-angle glaucoma: Treatment"
Daily Health News
Eye Health Resources
Subscribe to MedicineNet's General Health Newsletter
Last Editorial Review: 9/27/2017